2012

Completed a $65 million Series D financing to prepare the Company for PT003 Phase 3 program start in 2013

Completed the last two studies in a rigorous nine-study Phase 2 program of PT003 and its components, identifying optimal doses of the combination and monotherapy candidates for use in Phase 3 (See summary on http://clinicaltrials.gov or press releases)

Developed a triple combination - PT010 (Formoterol - Glycopyrrolate – Inhaled Corticosteroid) HFA-MDI formulation candidate suitable for clinical testing, without a change in drug delivery of each active relative to the mono-therapies and to the dual combinations